Description 223Ra-Radium Dichloride (Xofigo), also known as Radium-223 dichloride, BAY88-8223, or Xofigo® (formerly 223Ra-Alpharadin), is a radioactive salt developed by Algeta ASA. It targets cancers that commonly metastasize to the bone. Unlike earlier radiotherapeutics, which were limited to pain palliation, 223Ra has demonstrated a significant improvement in overall survival (OS)… Continue Reading…
Description 188Re-Rhenium Colloidal Sulfide is a specialized radiopharmaceutical treatment utilized in isotopic radiation synovectomy for addressing conditions in large-sized joints. This therapy delivers localized radiation directly to the affected joint to alleviate symptoms associated with arthritis and other joint disorders. Clinical Applications 188Re-Rhenium Colloidal Sulfide serves as the 188Re analogue… Continue Reading…
Description 188Re-HDD/Lipiodol, also known as 188Re-4-hexadecyl-1,2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol/Lipiodol or its acetylated variant 188Re-AHDD-Lipiodol, is a therapeutic agent that combines iodinated fatty acid ethyl esters derived from poppy seed oil (marketed as Lipiodol™) with a radioactive rhenium complex. The acetylated form, AHDD-Lipiodol, incorporates acetyl groups to stabilize the sulfhydryl components in its formulation.… Continue Reading…
Description 188Re-Rhenium Etidronate, also known by its various designations such as 186Re-HEDP, hydroxyethylidene diphosphonate, 186Re-Etidronate, 188Re-Hydroxyethanediphosphonate, and 188Re-REK-1, is a radiopharmaceutical agent with significant applications in medical treatments. It is commercially available in India through BRIT/BARC for radiosynovectomy procedures. This compound is also being actively developed as a therapeutic agent… Continue Reading…
Description186Re-Rhenium Colloidal Sulfide is a widely recognized therapeutic agent employed in isotopic radiation synovectomy for treating medium-sized joints. This generic formulation, designated as 186Re-Rhenium Colloidal Sulfide, is particularly effective in delivering localized radiotherapy to joints affected by various arthritic conditions. Clinical ApplicationsThis formulation is primarily indicated for patients with rheumatoid… Continue Reading…
Description186Re-Rhenium Etidronate (commonly referred to as 186Re-HEDP, hydroxyethylidene diphosphonate, or 186Re-Etidronate) is a radiopharmaceutical developed by Mallinckrodt for palliating bone pain caused by metastatic bone cancer. This innovative formulation was initially approved and launched in Switzerland and Greece. However, despite its potential, the New Drug Application (NDA) submitted to the… Continue Reading…
Description 177Lu-Oxodotreotide (also known as 177Lu-Lutathera®, 177Lu-DOTATATE, and Lutetium-177 dotatate) is a somatostatin analogue developed for the treatment of neuroendocrine tumors (NETs). It was the first 177Lu-labeled molecule to receive marketing authorization. The drug was originally developed by Biosynthema, which was acquired by Advanced Accelerator Applications (AAA) in 2010. The… Continue Reading…
What is 177Lu-EDTMP? 177Lu-EDTMP (Lutetium-177 ethylenediaminetetramethylene phosphonate) is a radiopharmaceutical therapy developed for bone pain palliation in cancer patients, specifically those with bone metastases, such as from prostate cancer. It serves as an alternative to 153Sm-EDTMP (Lexidronam), commonly known as Quadramet®, which was widely used for the same indication. Although… Continue Reading…
What is 169Er-Erbium Citrate? 169Er-Erbium Citrate is a specialized radiopharmaceutical therapy designed for isotopic radiation synovectomy, particularly targeting small joints such as those in the hands and feet. This treatment leverages the therapeutic benefits of radioactive isotopes to alleviate symptoms of joint-related conditions. Clinical Applications of 169Er-Erbium Citrate This therapy… Continue Reading…
Overview166Ho-Chitosan, also known as DW166-HC, is an innovative radiopharmaceutical drug designed for targeted cancer therapy. Commercially available under the brand name Milican in South Korea, it was developed by Dong Wha Pharmaceuticals and launched in August 2001. This therapeutic agent offers a novel approach for treating hepatocellular carcinoma (HCC), leveraging… Continue Reading…
Description 166Ho-QuiremSpheres (also known as 166Ho-PLLA-MS) is a medical device developed at the University Medical Center Utrecht in the Netherlands. The product consists of microparticles loaded with the radioactive isotope Holmium-166. These microparticles are created by activating 165Ho pre-loaded poly-L-lactic acid (PLLA) particles with neutron flux in a reactor, using… Continue Reading…
Description 153Sm-Oxabiphor, also known as Samarium-153 oxa-bis(ethylenedithio)tetramethylphosphonium acid, is a radiopharmaceutical used for pain relief in patients with osteoblastic skeletal metastases. These metastases typically show up on a 99mTc-bisphosphonate bone scan. 153Sm-Oxabiphor was developed to bypass existing patents and territory restrictions, making it more accessible in certain regions. The drug… Continue Reading…